PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 10 | 1 |
Article title

Mastoscopic sentinel lymph node biopsy in breast
cancer

Content
Title variants
Languages of publication
EN
Abstracts
EN
Background: Previous studies have demonstrated
that mastoscopic sentinel lymph node biopsy
(MSLNB) has good identification rate (IR) and low false
negative rate (FNR). However, few studies have directly
compared the surgical performance and peri- and post-operative
factors of MSLNB with conventional sentinel lymph
node biopsy (SLNB). Methodology: Sixty patients diagnosed with breast cancer
were recruited and randomly assigned to one of the three
groups: MSLNB, SLNB and SLNB with lipolysis injection.
Peri- and post-operative parameters were compared using
general linear models. To examine the effect of age on
these parameters, we performed separate analysis stratified
by age (≤50 years old vs. >50 years old). Results: Patients in the MSLNB group experienced longer
surgery and suffered higher surgical cost than patients
who underwent conventional SLNB or SLNB with lipolysis
injection (p<0.0001). Despite this, they had significantly
less blood loss than those who underwent conventional
SLNB (22.0±7.0 ml vs.73.5±39.6 ml; p<0.0001). Analysis by
age group indicates a similar pattern of difference among
the three groups. MSLNB and conventional SLNB have
similar IR and FNR. Conclusion: As a minimally invasive technique, MSLNB
can significantly reduce blood loss while providing similar
IR and FNR, indicating that it can be a promising alternative
to conventional SLNB. Conclusion: Variations in popliteal artery terminal
branching pattern occurred in 7.4% to 17.6% of patients.
Pre-surgical detection of these variations with MD CTA
may help to reduce the risk of iatrogenic arterial injury by
enabling a better surgical treatment plan.
Publisher
Journal
Year
Volume
10
Issue
1
Physical description
Dates
accepted
14 - 9 - 2015
received
17 - 2 - 2015
online
26 - 10 - 2015
References
  • [1] Ernst M.F., Voogd A.C., Balder W., Klinkenbijl J.H., and RoukemaJ.A., Early and late morbidity associated with axillary levels I-IIIdissection in breast cancer, J Surg Oncol, 2002, 79, 151-155;discussion 156[Crossref]
  • [2] Hack T.F., Cohen L., Katz J., Robson L.S., and Goss P., Physicaland psychological morbidity after axillary lymph nodedissection for breast cancer, J Clin Oncol, 1999, 17, 143-149[Crossref]
  • [3] Lyman G.H., Giuliano A.E., Somerfield M.R., Benson A.B., 3rd,Bodurka D.C., Burstein H.J., et al., American Society of ClinicalOncology guideline recommendations for sentinel lymph nodebiopsy in early-stage breast cancer, J Clin Oncol, 2005, 23,7703-7720[Crossref]
  • [4] Giuliano A.E., McCall L., Beitsch P., Whitworth P.W.,Blumencranz P., Leitch A.M., et al., Locoregional recurrenceafter sentinel lymph node dissection with or without axillarydissection in patients with sentinel lymph node metastases:the American College of Surgeons Oncology Group Z0011randomized trial, Ann Surg, 2010, 252, 426-432; discussion432-423
  • [5] Giuliano A.E., Hunt K.K., Ballman K.V., Beitsch P.D., WhitworthP.W., Blumencranz P.W., et al., Axillary dissection vs no axillarydissection in women with invasive breast cancer and sentinelnode metastasis: a randomized clinical trial, JAMA, 2011, 305,569-575[WoS]
  • [6] Veronesi U., Viale G., Paganelli G., Zurrida S., Luini A.,Galimberti V., et al., Sentinel lymph node biopsy in breastcancer: ten-year results of a randomized controlled study, AnnSurg, 2010, 251, 595-600[WoS]
  • [7] Belmonte R., Garin O., Segura M., Pont A., Escalada F., andFerrer M., Quality-of-life impact of sentinel lymph nodebiopsy versus axillary lymph node dissection in breast cancerpatients, Value Health, 2012, 15, 907-915[Crossref]
  • [8] Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P.,Ashikaga T., et al., Technical outcomes of sentinel-lymph-noderesection and conventional axillary-lymph-node dissection inpatients with clinically node-negative breast cancer: resultsfrom the NSABP B-32 randomised phase III trial, Lancet Oncol,2007, 8, 881-888[WoS][Crossref]
  • [9] Luo C., Guo W., Yang J., Sun Q., Wei W., Wu S., et al.,Comparison of mastoscopic and conventional axillary lymphnode dissection in breast cancer: long-term results froma randomized, multicenter trial, Mayo Clin Proc, 2012, 87,1153-1161[WoS][Crossref]
  • [10] Lee E.-K., Park Y.-L., and Pae W.-K., [Endoscopic Sentinel NodeBiopsy], Journal of Breast Cancer, 2003, 6, 174-179
  • [11] Woo H.-D., Han S.-W., Son D.-M., Kim S.-Y., Lim C.-W., and LeeM.-H., [Endoscopic sentinel lymph node biopsy in breast cancersurgery: feasibility and accuracy of the combined radioisotopeand blue dye], Journal of Breast Cancer, 2010, 13, 59-64[WoS][Crossref]
  • [12] Cody H.S., 3rd and Borgen P.I., State-of-the-art approaches tosentinel node biopsy for breast cancer: study design, patientselection, technique, and quality control at Memorial Sloan-Kettering Cancer Center, Surg Oncol, 1999, 8, 85-91[Crossref]
  • [13] Brown L.D., Cai T., and DasGupta A., Interval estimation for abinomial proportion, Statistical Science, 2001, 16, 101-198
  • [14] Edwards D. and Berry J.J., The efficiency of simulation-basedmultiple comparisons, Biometrics, 1987, 43, 913-928[Crossref]
  • [15] Cody H.S., 3rd, Sentinel lymph node mapping in breast cancer,Breast Cancer, 1999, 6, 13-22[Crossref]
  • [16] Miltenburg D.M., Miller C., Karamlou T.B., and Brunicardi F.C.,Meta-analysis of sentinel lymph node biopsy in breast cancer, JSurg Res, 1999, 84, 138-142[Crossref]
  • [17] National Bureau of Statistics of the People’s Republic of China.Good and steady development of the national economy ofChina in 2013. 2014 [cited 2014 01/23/2014]; Available from:http://www.stats.gov.cn/tjsj/zxfb/201401/t20140120_502082.html.
  • [18] Kootstra J., Hoekstra-Weebers J.E., Rietman H., de Vries J., BaasP., Geertzen J.H., et al., Quality of life after sentinel lymph nodebiopsy or axillary lymph node dissection in stage I/II breastcancer patients: a prospective longitudinal study, Ann SurgOncol, 2008, 15, 2533-2541[Crossref]
  • [19] Zhang H., Li X., Xiang K., Hu G., and Ding B., [Value of lipolyticsolution injection in axillary lymph node dissection for breastcancer], Chinese Journal of General Surgery, 2013, 22, 551-554
  • [20] Mu W., Li Y., Tong X., Yang Q., and Song F., [The hemostaticeffect of preincisional subcutaneous drug injection in breastcancer], Chinese Journal of General Surgery, 2012, 21, 627-630
  • [21] Yamashita K. and Haga S., 3D-CT mammary lymphography forsentinel node biopsy, Nihon Rinsho, 2012, 70 Suppl 7, 377-380
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_1515_med-2015-0057
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.